Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report on the final planned analysis of OPTiM, a randomized open-label phase III trial of T-vec in patients with unresectable stage IIIB–IVM1c melanoma. Authors: Robert H. I. Andtbacka , Frances Collichio , Kevin J....
Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article reporting the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201. Authors: Mark N. Stein , Jyoti Malhotra , Rohinton S. Tarapore , Usha...
Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article concluding that ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations. Authors: Douglas B....
Published in the Journal for ImmunoTherapy of Cancer (JITC), is a position article and guidelines. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of...
Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report discussing a phase II clinical trial investigating the feasibility of intermittent nivolumab dosing in RCC. JITC (2019) 7 :127 Authors: Moshe C. Ornstein , Laura S. Wood , Brian P. Hobbs , Kimberly D. Allman ...
This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers May Cho, MD, and Terence Rhodes, MD, PhD provided...
Advances in Cancer Immunotherapy Webinar Series - Updates from the Field - Clinical Updates from ESMO IO Congress 2018.pdf
This webinar provided an update on developments in the field relating to content presented at the Advances in Cancer Immunotherapy programs and focused on applicable information for a clinical audience. More specifically, program organizers Christian M. Capitini, MD, and Zachary S. Morris,...
Advances in Cancer Immunotherapy Updates from the Field - Clinical Updates from SITC 2018.pdf
Organizers Robert Canter, MD, MAS, FACS, and Robert L. Ferris, MD, PhD provided an update on developments in the cancer immunotherapy field relating to content presented at the Advances in Cancer Immunotherapy TM programs and focused on applicable information for a clinical audience. ...
Advances in Cancer Immunotherapy Webinar Series - Updates from AACR.pdf
Edited By: Marc S. Ernstoff, MD – Roswell Park Comprehensive Cancer Center Igor Puzanov, MD, MSCI, FACP – Roswell Park Comprehensive Cancer Center Caroline Robert, MD, PhD – Institut Gustave Roussy Adi Diab, MD – The University of Texas MD Anderson Cancer Center Peter Hersey, MD, PhD – ...
LUNGevity sat down with Patrick Forde, MD (MB, BCH), Associate Professor of Oncology at the Johns Hopkins School of Medicine, to discuss the results of the PACIFIC trial and what it means for the lung cancer survivor community. Dr. Forde is an expert on immunotherapies for lung cancer and has...
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us